Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being ...

Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global ...

After being found effective over longer durations with smaller doses, this study found that nipocalimab infusions resulted in a tolerable safety profile and remained effective even in shorter ...

A home-infusion model combining remote physiologic monitoring, virtual command center supervision, and in-home nursing enabled delivery of 93 IV chemotherapy infusions without infusion reactions or ...

This episode, titled Optimizing Subcutaneous Therapies in NSCLC: Practical Integration, Patient Selection, and Workflow ...

While Eli Lilly’s investigational monoclonal antibody drug, bamlanivimab, just received FDA emergency approval to treat mild coronavirus patients, top officials voiced concerns over its challenging IV ...

Intravenous lidocaine infusion has emerged as a promising adjunct for postoperative pain management, offering a potential alternative to conventional opioid‐based strategies and regional techniques ...

Stroke patients treated intravenously with loberamisal, a novel neuroprotective medication, daily for 10 days and starting within 48 hours of stroke symptoms, had better recovery than patients who ...

The sizes of microplastics ranged from 1 to 62 µm, with a median of about 8.5 µm. HealthDay News — Microplastics appear to be present in filtered solutions used for medical intravenous infusions, with ...

They can be spotted in Las Vegas and at select spots across the country, including festivals like Coachella: shops that give IV infusions to customers who are looking for relief from hangovers or just ...

The Alzheimer’s drug Leqembi, the first medicine proven to slow the course of the disease, may be able to be given as a set of two weekly shots at home, a study from drugmaker Eisai suggests, ...